AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 62 min read$NTRA

Chapman Steven Leonard sold $774K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 3,409 shares of Natera, Inc. (NTRA) at $226.97 ($0.77M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not, by itself, provide new business performance or forward-looking guidance.

02

Market read

Primarily sentiment/positioning noise; limited fundamental read-through due to 10b5-1 pre-arrangement.

03

What to watch

Traders may overweight insider selling; the key mitigating detail is the pre-arranged 10b5-1 plan, which often reduces signal strength.

Relevance 6/10Novelty 3/10Timing: Filed June 5 for a June 4 sale; disclosure may affect intraday sentiment.

Background

SEC Form 4 insider transaction: CEO/president Chapman Steven Leonard sold 3,409 NTRA shares at ~$226.97 on June 4, with a stated 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold $773.7K of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Near-term price reaction likely muted; any move would be more sentiment/positioning-driven than fundamentals.

Evidence & confidence

The filing is a routine insider transaction disclosure and explicitly references a pre-arranged 10b5-1 plan, reducing interpretability as new negative information.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated operational/regulatory/clinical catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • issuer
    Natera, Inc.

    Subject of the Form 4 insider sale by its CEO/president under a 10b5-1 plan.

  • insider
    Chapman Steven Leonard

    CEO and President who executed the open-market sale.

Read at source← All news

Related articles

AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

timothysykes.com6 min
AUG 7
$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

benzinga.com4 min
AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min